- Home
- SFWL vs ACET Comparison
SFWL vs ACET Comparison
Compare SFWL & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SFWL
- ACET
- Stock Information
- Founded
- SFWL 2001
- ACET 1947
- Country
- SFWL China
- ACET United States
- Employees
- SFWL N/A
- ACET N/A
- Industry
- SFWL Trucking Freight/Courier Services
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- SFWL Industrials
- ACET Health Care
- Exchange
- SFWL Nasdaq
- ACET Nasdaq
- Market Cap
- SFWL 80.8M
- ACET 70.3M
- IPO Year
- SFWL 2023
- ACET N/A
- Fundamental
- Price
- SFWL $0.98
- ACET $0.79
- Analyst Decision
- SFWL
- ACET Buy
- Analyst Count
- SFWL 0
- ACET 6
- Target Price
- SFWL N/A
- ACET $6.00
- AVG Volume (30 Days)
- SFWL 10.3K
- ACET 305.9K
- Earning Date
- SFWL 04-08-2025
- ACET 03-06-2025
- Dividend Yield
- SFWL N/A
- ACET N/A
- EPS Growth
- SFWL 4.79
- ACET N/A
- EPS
- SFWL 0.13
- ACET N/A
- Revenue
- SFWL $504,158,000.00
- ACET N/A
- Revenue This Year
- SFWL N/A
- ACET N/A
- Revenue Next Year
- SFWL N/A
- ACET N/A
- P/E Ratio
- SFWL $7.43
- ACET N/A
- Revenue Growth
- SFWL 24.75
- ACET N/A
- 52 Week Low
- SFWL $0.81
- ACET $0.74
- 52 Week High
- SFWL $2.23
- ACET $2.43
- Technical
- Relative Strength Index (RSI)
- SFWL 42.77
- ACET 44.00
- Support Level
- SFWL $0.96
- ACET $0.74
- Resistance Level
- SFWL $1.04
- ACET $0.91
- Average True Range (ATR)
- SFWL 0.04
- ACET 0.06
- MACD
- SFWL -0.00
- ACET 0.01
- Stochastic Oscillator
- SFWL 23.56
- ACET 27.18
About SFWL Shengfeng Development Limited
Shengfeng Development Ltd is a holding company. The company offers contract logistics services comprising planning and designing supply chains, designing facilities, processing orders, collecting payments, managing inventories, and providing client services. The integrated logistics solution services of the company are comprised of three segments: B2B freight transportation; cloud storage; and value-added services.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.